Search Results

Site Search

Activity Metrics Dashboard - Insights

We are excited to share that the Activity Metrics Dashboard is now live on mayocliniclabs.com. We heard your feedback and created these reports to provide a more integrated, intuitive and customized experience on our website. 

Meet Me at the Microscope at USCAP 2020 - Insights

Mayo Clinic pathologists, researchers, and a wide spectrum of allied health staff will be in Los Angeles, California, for the 109th United States and Canadian Academy of Pathology Meeting (USCAP). Visit us at booth #716 on March 2 - 4, 2020...

FISH testing - Insights

Find out how our streamlined approach to fluorescence in situ hybridization testing can simplify the ordering process and better meet patient needs.

MayoComplete - Insights

Browse our menu of MayoComplete next-generation sequencing assays which are designed to identify a growing list of hematological cancers.

Primary ciliary dyskinesia - Insights

Learn more about Mayo Clinic Laboratories’ robust approach to testing for primary ciliary dyskinesia, a rare genetic condition that can lead to chronic otosinopulmonary disease and infertility in men.

Diagnostic and companion testing - Insights

Learn more about how diagnostic and companion testing can confirm a prenatal genetic diagnosis.

Lysosomal metabolism and storage disorders - Insights

Learn more about how Mayo Clinic Laboratories’ comprehensive menu of biochemical and molecular testing can clarify diagnosis of a lysosomal metabolism and storage disorder.

Cholesterol biosynthesis and transport - Insights

Check out Mayo Clinic Laboratories’ testing approach to diagnose disorders related to cholesterol biosynthesis and transport.

Pan cancer - Insights

Learn about our comprehensive MayoComplete solid tumor panel, which analyzes 515 genes for mutations, rearrangements, and amplifications.

Lung Cancer NGS Panel - Mayo Clinic Laboratories

Our targeted lung cancer panel assesses for mutations in eight genes, and rearrangements in four genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.